NEXSTIM PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.97 EUR | -1.00% |
|
-9.17% | +1.02% |
| Sales 2024 * | 9.3M 9.94M 831M | Sales 2025 * | 11.7M 12.51M 1.05B | Capitalization | 20.09M 21.48M 1.8B |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 0 | Net income 2025 * | - 0 0 | EV / Sales 2024 * | 2.28 x |
| Net Debt 2024 * | 1.1M 1.18M 98.31M | Net Debt 2025 * | 300K 321K 26.81M | EV / Sales 2025 * | 1.74 x |
| P/E ratio 2024 * |
-297
x | P/E ratio 2025 * |
22.8
x | Employees | 37 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 51.18% |
More Fundamentals
* Assessed data
More news
Latest transcript on Nexstim Plc
More press releases
| 1 day | -1.00% | ||
| 1 week | -9.17% | ||
| Current month | +6.83% | ||
| 1 month | +3.12% | ||
| 3 months | +35.62% | ||
| 6 months | +17.39% | ||
| Current year | +1.02% |
1 week
2.90
3.20
1 month
2.664.60
Current year
2.104.60
1 year
2.034.60
3 years
2.036.20
5 years
1.5227.40
10 years
1.5223 100.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 47 | 18/14/18 | |
| Director of Finance/CFO | 38 | 01/14/01 | |
Gustaf Järnefelt
CTO | Chief Tech/Sci/R&D Officer | 63 | 01/08/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 62 | 11/19/11 | |
| Director/Board Member | 53 | 01/21/01 | |
| Director/Board Member | 65 | 01/21/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/24/20 | 2.97 | -1.00% | 6,249 |
| 19/24/19 | 3 | +1.69% | 9,184 |
| 18/24/18 | 2.95 | -4.84% | 10,417 |
| 17/24/17 | 3.1 | -3.13% | 11,973 |
| 14/24/14 | 3.2 | -2.14% | 11,882 |
Delayed Quote Nasdaq Helsinki, June 20, 2024 at 09:30 pm IST
More quotes
Nexstim Oyj is a Finland-based medical technology company. It is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Companyâs systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.
Calendar
31/07/2024
- NYC Neuromodulation Conference
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
1
Last Close Price
2.97
EUR
Average target price
3.4
EUR
Spread / Average Target
+14.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.02% | 21.53M | |
| +6.39% | 213B | |
| +10.19% | 184B | |
| +28.26% | 153B | |
| +34.53% | 113B | |
| +0.80% | 63.66B | |
| +19.27% | 53.53B | |
| +0.13% | 49.11B | |
| -4.16% | 38.73B | |
| +2.38% | 36.26B |
- Stock Market
- Equities
- NXTMH Stock
